Article Text

PDF
Leflunomide: a possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections
  1. T D Sudarsanam1,
  2. R D Sahni2,
  3. G T John3
  1. 1Department of Medicine, CMC, Vellore, India
  2. 2Department of Microbiology, CMC, Vellore
  3. 3Department of Nephrology, CMC, Vellore
  1. Correspondence to:
 Dr T D Sudarsanam
 Department of Medicine, CMC, Vellore, 632004, India; thambu{at}cmcvellore.ac.in

Abstract

The search for newer more cost effective treatments for infectious diseases remains a challenge. Cytomegalovirus (CMV) infection, which is especially common in the immunosupressed, is an important challenge for treating physicians. Gangciclovir’s cost is a major hurdle in developing countries. Leflunomide is cheaper and is easily given orally. It works by a novel mechanism inhibiting virion assembly. It also has immunosuppressive properties. It and has been shown to be effective in both gangciclovir sensitive as well as resistant cases of CMV infection. Given these considerations we believe that leflunomide is an exiting new drug for CMV infection. However, hepatotoxicity and teratogenicity are known side effects. The exact dose and duration of treatment for CMV infection, for secondary prophylaxis, and in situations of gangciclovir resistance need further study.

  • leflunomide
  • cytomegalovirus
  • infection
  • gangciclovir
  • resistance

Statistics from Altmetric.com

Footnotes

  • Funding: none.

  • Conflicts of interest: none declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.